对 CGRP 的超敏反应是使用艾伦单抗预防偏头痛的预测性生物标志物。

IF 5 2区 医学 Q1 CLINICAL NEUROLOGY
Haidar M Al-Khazali, Håkan Ashina, Rune Häckert Christensen, Astrid Wiggers, Kathrine Rose, Afrim Iljazi, Faisal Mohammad Amin, Messoud Ashina, Josefin Snellman, Tina Maio-Twofoot, Henrik W Schytz
{"title":"对 CGRP 的超敏反应是使用艾伦单抗预防偏头痛的预测性生物标志物。","authors":"Haidar M Al-Khazali, Håkan Ashina, Rune Häckert Christensen, Astrid Wiggers, Kathrine Rose, Afrim Iljazi, Faisal Mohammad Amin, Messoud Ashina, Josefin Snellman, Tina Maio-Twofoot, Henrik W Schytz","doi":"10.1177/03331024241258734","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The present study aimed to investigate the predictive value of calcitonin gene-related peptide (CGRP)-induced migraine attacks for effectiveness to erenumab treatment in people with migraine.</p><p><strong>Methods: </strong>In total, 139 participants with migraine underwent a single experimental day involving a 20-min infusion with CGRP. Following this, the participants entered a 24-week treatment period with erenumab. The primary endpoints were the predictive value of CGRP-induced migraine attacks on the effectiveness of erenumab, defined as ≥50% reduction in monthly migraine days, or ≥ 50% reduction in either monthly migraine or monthly headache days of moderate to severe intensity.</p><p><strong>Results: </strong>Among participants with CGRP-induced migraine attacks, 60 of 99 (61%) achieved ≥50% reduction in monthly migraine days during weeks 13-24 with erenumab. Conversely, 13 of 25 (52%) where CGRP infusion did not induce a migraine achieved the same endpoint (<i>p</i> = 0.498). There were no significant differences between the ≥50% reduction in either monthly migraine or monthly headache days of moderate to severe intensity between CGRP-sensitive and non-sensitive participants (<i>p</i> = 0.625).</p><p><strong>Conclusions: </strong>Our findings suggest that the CGRP-provocation model cannot be used to predict erenumab's effectiveness. It remains uncertain whether this finding extends to other monoclonal antibodies targeting the CGRP ligand or to gepants.<b>Trial Registration:</b> The study was registered at ClinicalTrials.gov (NCT04592952).</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 6","pages":"3331024241258734"},"PeriodicalIF":5.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab.\",\"authors\":\"Haidar M Al-Khazali, Håkan Ashina, Rune Häckert Christensen, Astrid Wiggers, Kathrine Rose, Afrim Iljazi, Faisal Mohammad Amin, Messoud Ashina, Josefin Snellman, Tina Maio-Twofoot, Henrik W Schytz\",\"doi\":\"10.1177/03331024241258734\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The present study aimed to investigate the predictive value of calcitonin gene-related peptide (CGRP)-induced migraine attacks for effectiveness to erenumab treatment in people with migraine.</p><p><strong>Methods: </strong>In total, 139 participants with migraine underwent a single experimental day involving a 20-min infusion with CGRP. Following this, the participants entered a 24-week treatment period with erenumab. The primary endpoints were the predictive value of CGRP-induced migraine attacks on the effectiveness of erenumab, defined as ≥50% reduction in monthly migraine days, or ≥ 50% reduction in either monthly migraine or monthly headache days of moderate to severe intensity.</p><p><strong>Results: </strong>Among participants with CGRP-induced migraine attacks, 60 of 99 (61%) achieved ≥50% reduction in monthly migraine days during weeks 13-24 with erenumab. Conversely, 13 of 25 (52%) where CGRP infusion did not induce a migraine achieved the same endpoint (<i>p</i> = 0.498). There were no significant differences between the ≥50% reduction in either monthly migraine or monthly headache days of moderate to severe intensity between CGRP-sensitive and non-sensitive participants (<i>p</i> = 0.625).</p><p><strong>Conclusions: </strong>Our findings suggest that the CGRP-provocation model cannot be used to predict erenumab's effectiveness. It remains uncertain whether this finding extends to other monoclonal antibodies targeting the CGRP ligand or to gepants.<b>Trial Registration:</b> The study was registered at ClinicalTrials.gov (NCT04592952).</p>\",\"PeriodicalId\":10075,\"journal\":{\"name\":\"Cephalalgia\",\"volume\":\"44 6\",\"pages\":\"3331024241258734\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cephalalgia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/03331024241258734\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cephalalgia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03331024241258734","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

研究背景本研究旨在探讨降钙素基因相关肽(CGRP)诱导的偏头痛发作对偏头痛患者接受艾伦单抗治疗效果的预测价值:共有139名偏头痛患者接受了单日实验,其中包括20分钟的CGRP输注。之后,参与者进入为期24周的艾伦单抗治疗期。主要终点是CGRP诱导的偏头痛发作对艾伦单抗疗效的预测价值,即每月偏头痛天数减少≥50%,或每月偏头痛或每月中重度头痛天数减少≥50%:在CGRP诱发偏头痛发作的参与者中,99人中有60人(61%)在使用艾伦单抗的第13-24周期间每月偏头痛发作天数减少了≥50%。相反,在输注 CGRP 没有诱发偏头痛的 25 人中,有 13 人(52%)达到了同样的终点(p = 0.498)。对CGRP敏感和不敏感的参与者每月偏头痛或每月中重度头痛天数减少≥50%之间没有明显差异(p = 0.625):我们的研究结果表明,CGRP诱发模型不能用于预测艾伦单抗的疗效。目前仍不确定这一发现是否适用于其他靶向CGRP配体的单克隆抗体或抗凝血剂:该研究已在ClinicalTrials.gov(NCT04592952)上注册。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab.

Background: The present study aimed to investigate the predictive value of calcitonin gene-related peptide (CGRP)-induced migraine attacks for effectiveness to erenumab treatment in people with migraine.

Methods: In total, 139 participants with migraine underwent a single experimental day involving a 20-min infusion with CGRP. Following this, the participants entered a 24-week treatment period with erenumab. The primary endpoints were the predictive value of CGRP-induced migraine attacks on the effectiveness of erenumab, defined as ≥50% reduction in monthly migraine days, or ≥ 50% reduction in either monthly migraine or monthly headache days of moderate to severe intensity.

Results: Among participants with CGRP-induced migraine attacks, 60 of 99 (61%) achieved ≥50% reduction in monthly migraine days during weeks 13-24 with erenumab. Conversely, 13 of 25 (52%) where CGRP infusion did not induce a migraine achieved the same endpoint (p = 0.498). There were no significant differences between the ≥50% reduction in either monthly migraine or monthly headache days of moderate to severe intensity between CGRP-sensitive and non-sensitive participants (p = 0.625).

Conclusions: Our findings suggest that the CGRP-provocation model cannot be used to predict erenumab's effectiveness. It remains uncertain whether this finding extends to other monoclonal antibodies targeting the CGRP ligand or to gepants.Trial Registration: The study was registered at ClinicalTrials.gov (NCT04592952).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cephalalgia
Cephalalgia 医学-临床神经学
CiteScore
10.10
自引率
6.10%
发文量
108
审稿时长
4-8 weeks
期刊介绍: Cephalalgia contains original peer reviewed papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications. Published monthly on behalf of the International Headache Society, Cephalalgia''s rapid review averages 5 ½ weeks from author submission to first decision.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信